935 related articles for article (PubMed ID: 19614963)
1. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
Putzki N; Yaldizli O; Bühler R; Schwegler G; Curtius D; Tettenborn B
Eur Neurol; 2010; 63(2):101-6. PubMed ID: 20090344
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
Putzki N; Kollia K; Woods S; Igwe E; Diener HC; Limmroth V
Eur J Neurol; 2009 Mar; 16(3):424-6. PubMed ID: 19187261
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
5. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
7. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
8. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
13. Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.
Mäurer M; Dachsel R; Domke S; Ries S; Reifschneider G; Friedrich A; Knorn P; Landefeld H; Niemczyk G; Schicklmaier P; Wernsdörfer C; Windhagen S; Albrecht H; Schwab S;
Eur J Neurol; 2011 Aug; 18(8):1036-45. PubMed ID: 21199183
[TBL] [Abstract][Full Text] [Related]
14. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
15. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Romeo M; Martinelli-Boneschi F; Rodegher M; Esposito F; Martinelli V; Comi G;
Eur J Neurol; 2013 Jul; 20(7):1060-7. PubMed ID: 23425504
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
[TBL] [Abstract][Full Text] [Related]
18. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
